Patent intelligence · US
US 12364680
Compounds for treating ophthalmic diseases and disorders
Compounds for treating ophthalmic diseases and disorders
Patent details — US 12364680
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 22, 2025
- Expiration
- Jul 17, 2045
- Applicant
- KIORA PHARMACEUTICALS GmbH
- Claims
- 16
- CPC classes
- A61K, A61K31/196, A61K31/277, A61K31/341
Quick answer
US 12364680 (Compounds for treating ophthalmic diseases and disorders) is held by KIORA PHARMACEUTICALS GmbH. Status: granted. Granted Jul 22, 2025. Expires Jul 17, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- KIORA PHARMACEUTICALS GmbH
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K31/196, A61K31/277, A61K31/341, A61K31/381, A61K31/42
More from KIORA PHARMACEUTICALS GmbH
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 12364680?
US 12364680 (Compounds for treating ophthalmic diseases and disorders) is held by KIORA PHARMACEUTICALS GmbH. Status: granted. Granted Jul 22, 2025. Expires Jul 17, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12364680?
KIORA PHARMACEUTICALS GmbH is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 12364680 expire?
Our index shows an expiration date of Jul 17, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.